$22.35
2.34% today
Nasdaq, Feb 28, 05:50 pm CET
ISIN
US74340E1038
Symbol
PGNY

Progyny Inc Stock price

$22.88
-0.07 0.31% 1M
+1.29 5.98% 6M
+5.63 32.64% YTD
-17.91 43.91% 1Y
-16.48 41.87% 3Y
-3.76 14.11% 5Y
+6.94 43.54% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.12 0.52%
ISIN
US74340E1038
Symbol
PGNY
Sector
Industry

Key metrics

Market capitalization $1.95b
Enterprise Value $1.73b
P/E (TTM) P/E ratio 39.41
EV/FCF (TTM) EV/FCF 10.80
EV/Sales (TTM) EV/Sales 1.52
P/S ratio (TTM) P/S ratio 1.71
P/B ratio (TTM) P/B ratio 4.65
Revenue growth (TTM) Revenue growth 10.24%
Revenue (TTM) Revenue $1.14b
EBIT (operating result TTM) EBIT $65.47m
Free Cash Flow (TTM) Free Cash Flow $160.41m
Cash position $235.72m
EPS (TTM) EPS $0.58
P/E forward 42.43
P/S forward 1.71
EV/Sales forward 1.52
Short interest 17.08%
Show more

Is Progyny Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Progyny Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Progyny Inc forecast:

3x Buy
30%
7x Hold
70%

Analyst Opinions

10 Analysts have issued a Progyny Inc forecast:

Buy
30%
Hold
70%

Financial data from Progyny Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,139 1,139
10% 10%
100%
- Direct Costs 892 892
11% 11%
78%
247 247
9% 9%
22%
- Selling and Administrative Expenses 178 178
3% 3%
16%
- Research and Development Expense - -
-
-
68 68
27% 27%
6%
- Depreciation and Amortization 2.94 2.94
41% 41%
0%
EBIT (Operating Income) EBIT 65 65
27% 27%
6%
Net Profit 57 57
10% 10%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Progyny Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Progyny Inc Stock News

Positive
The Motley Fool
about one hour ago
Progyny (PGNY -1.68%), a pioneer in fertility benefits management, released its earnings for the fourth quarter on Feb. 27. The standout points were its impressive revenue and adjusted earnings per share (EPS) results, both of which surpassed analysts' consensus predictions.
Neutral
Seeking Alpha
about 18 hours ago
Progyny, Inc. (NASDAQ:PGNY ) Q4 2024 Earnings Conference Call February 27, 2025 4:45 PM ET Company Participants James Hart - Investor Relations Pete Anevski - Chief Executive Officer Mark Livingston - Chief Financial Officer Michael Sturmer - President Conference Call Participants Anne Samuel - JPMorgan Michael Cherny - Leerink Partners John Pinney - Canaccord Genuity Scott Schoenhaus - KeyBanc...
Neutral
GlobeNewsWire
about 20 hours ago
Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% GrowthGenerated $52.2 Million of Quarterly Operating Cash FlowIssues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth
More Progyny Inc News

Company Profile

Progyny, Inc. is a medical device company. It engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. The firm operates through the following segments: medical device and fertility benefits solution. The company's services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.

Head office United States
CEO Peter Anevski
Employees 566
Founded 2008
Website www.progyny.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today